Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesProgression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer
Journal of Clinical Oncology, 06/15/09
Halabi S et al. - In a study to explore whether progression-free survival (PFS) or biochemical PFS can be used as a predictor of overall survival (OS) and to investigate the dependence between PFS and OS in men with castrate-resistant prostate cancer (PCa), it was reported that PFS at 3 and 6 mos and biochemical progression at 3 mos predict OS.
Methods- Data from nine Cancer and Leukemia Group B trials that enrolled 1296 men were pooled.
- Men were eligible if they had PCa that had progressed during androgen deprivation therapy and did not receive prior treatment with chemotherapy, immunotherapy, or other nonhormonal therapy.
- Landmark analyses of PFS at 3 and 6 mos from randomization/registration were performed to minimize lead time bias.
- Proportional hazards model was used to assess the significance effect of PFS rate at 3 and 6 mos in predicting OS.
- Biochemical progression using the definitions of Prostate-Specific Antigen Working Group (PSAW) Criteria PSAWG1 and PSAWG2 were analyzed as time-dependent covariates in predicting OS.
- Median survival time among men who experienced progression at 3 mos was 9.2 mos compared with 17.8 mos in men who did not experience progression at 3 mos.
- Compared with men who did not progress at 3 and 6 mos, the adjusted hazard ratios for death were 2.0 and 1.9 for men who experienced progression at 3 and 6 mos, respectively.
- Biochemical progression at 3 mos predicted OS.
- Association between PFS and OS was 0.30.
Related Articles
Phase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanoma
Journal of Clinical Oncology, 11/19/09
Relevance Score: 67%
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Relevance Score: 67%
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: CCTGcctg and SWOG study N0426
Journal of Clinical Oncology, 10/26/09
Relevance Score: 66%
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced NSCLC
Journal of Clinical Oncology, 10/20/09
Relevance Score: 66%
The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients
Journal of Cancer Research & Clinical Oncology, 10/01/09
Relevance Score: 65%
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
European Urology, 12/04/09
Article Search
Sponsor